Super Sam Foundation Reaffirms Support for Oncoheroes' Pediatric Cancer Drive

por Oncoheroes Biosciences

2 years ago
volasertib, pediatric cancer, Oncoheroes Biosciences

As Oncoheroes prepares to evaluate the efficacy of its lead compound, volasertib, across five pediatric cancer indications, including rhabdomyosarcoma, the Super Sam Foundation once again steps forwar...

Vall d’Hebron Research Institute (VHIR) and Oncoheroes Biosciences to Partner for the Discovery and Development of Novel Therapies for Childhood Sarcomas

por Oncoheroes Biosciences

4 years ago
pediatric sarcomas, rhabdomyosarcoma (RMS), Vall d’Hebron Research Institute (VHIR), Oncoheroes Biosciences

Vall d’Hebron Research Institute (VHIR), a world-leading healthcare institution where healthcare, research, innovation and education go hand in hand, and Oncoheroes Biosciences, a biotech company ex...

Oncoheroes Biosciences and Allarity Therapeutics Sign Exclusive Pediatric Licensing Agreement for Dovitinib and Stenoparib

por Oncoheroes Biosciences

5 years ago
Oncoheroes Biosciences, Allarity Therapeutics, children’s cancer, FDA, Dovitinib, Stenoparib

OncoheroeOncoheroes Biosciences, Inc. (“Oncoheroes”), and Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”) have signed a worldwide, exclusive pediatric licensing agreement for dovitinib...

WEBINAR: Why Childhood Cancer Foundations Are Adopting The Venture Philantropy Approach

por Oncoheroes Biosciences

5 years ago
Oncoheroes Biosciences, Childhood Cancer

Venture philanthropy is a growing trend across many important social issues.

Oncoheroes Biosciences receives a second investment from The Andrew McDonough B+ Foundation

por Oncoheroes Biosciences

5 years ago
Andrew McDonough B+ Foundation, Oncoheroes Biosciences, childhood cancer

In October 2019, The Andrew McDonough B+ Foundation invested for the first time in Oncoheroes Biosciences, a biotech company advancing new therapies for childhood cancer.